MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
Breast Cancer
Chemosensitivity
Combination therapy
Paclitaxel
miR-138-5p
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
27
05
2023
accepted:
25
07
2023
medline:
26
9
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Chemotherapy is a predominant strategy for breast cancer (BC) treatment and paclitaxel (PTX) has been known as a conventional chemotherapeutic drug. However, insensitivity of BC cells to PTX limits the anti-tumor effects of this agent. MicroRNAs are closely related to BC which are suggested as therapeutic factors in the combination therapy of BC. We examined the possible efficacy of miR-138-5p restoration in combination with PTX to impove BC treatment. The human breast cancer cell line MDA-MB-231 was transfected with miR-138-5p mimics and treated with PTX, in a combined or separate manner. The MTT assay was accomplished to determine inhibitory doses of PTX. Annexin V/PI assay and DAPI staining were applied to evaluate apoptosis. Flow cytometry was applied to determine cells arrested in different phases of the cell-cycle. Expression levels of molecular factors involved in cell migration, proliferation, apoptosis, and cell cycle were determined via western blotting and qRT-PCR. MiR-138-5p combined with PTX suppressed cell migration via modulating MMP2, E-cadherin, and vimentin and sustained colony formation and proliferation by downregulation of the PI3K/AKT pathway. qRT-PCR showed that miR-138-5p increases BC chemosensitivity to PTX by regulating the apoptosis factors, including Bcl-2, Bax, Caspase 3, and Caspase 9. Moreover, miR-138-5p restoration and paclitaxel therapy combined arrest the cells in the sub-G Restored miR-138-5p intensified the chemosensitivity of MDA-MB-231 cell line to PTX, and the combination of miR-138-5p with PTX might represent a novel approach in BC treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Chemotherapy is a predominant strategy for breast cancer (BC) treatment and paclitaxel (PTX) has been known as a conventional chemotherapeutic drug. However, insensitivity of BC cells to PTX limits the anti-tumor effects of this agent. MicroRNAs are closely related to BC which are suggested as therapeutic factors in the combination therapy of BC. We examined the possible efficacy of miR-138-5p restoration in combination with PTX to impove BC treatment.
METHODS
METHODS
The human breast cancer cell line MDA-MB-231 was transfected with miR-138-5p mimics and treated with PTX, in a combined or separate manner. The MTT assay was accomplished to determine inhibitory doses of PTX. Annexin V/PI assay and DAPI staining were applied to evaluate apoptosis. Flow cytometry was applied to determine cells arrested in different phases of the cell-cycle. Expression levels of molecular factors involved in cell migration, proliferation, apoptosis, and cell cycle were determined via western blotting and qRT-PCR.
RESULTS
RESULTS
MiR-138-5p combined with PTX suppressed cell migration via modulating MMP2, E-cadherin, and vimentin and sustained colony formation and proliferation by downregulation of the PI3K/AKT pathway. qRT-PCR showed that miR-138-5p increases BC chemosensitivity to PTX by regulating the apoptosis factors, including Bcl-2, Bax, Caspase 3, and Caspase 9. Moreover, miR-138-5p restoration and paclitaxel therapy combined arrest the cells in the sub-G
CONCLUSIONS
CONCLUSIONS
Restored miR-138-5p intensified the chemosensitivity of MDA-MB-231 cell line to PTX, and the combination of miR-138-5p with PTX might represent a novel approach in BC treatment.
Identifiants
pubmed: 37620737
doi: 10.1007/s11033-023-08711-y
pii: 10.1007/s11033-023-08711-y
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
MicroRNAs
0
MIRN138 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8407-8420Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ferlay J et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953
pubmed: 30350310
doi: 10.1002/ijc.31937
Abotaleb M et al (2018) Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother 101:458–477
pubmed: 29501768
doi: 10.1016/j.biopha.2018.02.108
Walsh V, Goodman J (2002) From taxol to taxol®: the changing identities and ownership of an anti-cancer drug. Med Anthropol 21(3–4):307–336
pubmed: 12458837
doi: 10.1080/01459740214074
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253–265
pubmed: 15057285
doi: 10.1038/nrc1317
Rieder CL, Maiato H (2004) Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7(5):637–651
pubmed: 15525526
doi: 10.1016/j.devcel.2004.09.002
Blagosklonny MV (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6(1):70–74
pubmed: 17245109
doi: 10.4161/cc.6.1.3682
Yamada HY, Gorbsky GJ (2006) Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther 5(12):2963–2969
pubmed: 17172401
pmcid: 2596631
doi: 10.1158/1535-7163.MCT-06-0319
Pan Z, Avila A, Gollahon L (2014) Paclitaxel induces apoptosis in breast cancer cells through different calcium—regulating mechanisms depending on external calcium conditions. Int J Mol Sci 15(2):2672–2694
pubmed: 24549172
pmcid: 3958875
doi: 10.3390/ijms15022672
Marupudi NI et al (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Exp Opin Drug Saf 6(5):609–621
doi: 10.1517/14740338.6.5.609
Chen J et al (2018) Downregulation of miR–200c–3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncol Rep 40(6):3821–3829
pubmed: 30272330
Loh H-Y et al (2019) The regulatory role of microRNAs in breast cancer. Int J Mol Sci 20(19):4940
pubmed: 31590453
pmcid: 6801796
doi: 10.3390/ijms20194940
Chakraborty C et al (2018) The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. Oncotarget 9(11):10164
pubmed: 29515800
pmcid: 5839381
doi: 10.18632/oncotarget.24309
Zhao C et al (2019) MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer 26:817–825
pubmed: 31243644
doi: 10.1007/s12282-019-00989-w
Sha H-H et al (2017) MiR-138: a promising therapeutic target for cancer. Tumor Biology 39(4):1010428317697575
pubmed: 28378633
doi: 10.1177/1010428317697575
Rasoolnezhad M et al (2021) MiRNA-138–5p: a strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis. Eur J Pharmacol 896:173933
pubmed: 33545160
doi: 10.1016/j.ejphar.2021.173933
Yu C et al (2015) Upregulation of microRNA–138–5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. Mol Med Rep 12(4):5135–5140
pubmed: 26135834
doi: 10.3892/mmr.2015.4031
Yuan M et al (2020) MicroRNA–138 inhibits tumor growth and enhances chemosensitivity in human cervical cancer by targeting H2AX. Experimental and therapeutic medicine. 19(1):630–638
Yoo J-Y et al (2021) Microrna-138 increases chemo-sensitivity of glioblastoma through downregulation of survivin. Biomedicines 9(7):780
pubmed: 34356844
pmcid: 8301402
doi: 10.3390/biomedicines9070780
Liu L et al (2023) MiR-138–5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B. Translational Oncol 35:101723
doi: 10.1016/j.tranon.2023.101723
Dastmalchi N et al (2021) MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation. Mol Biol Rep 48:1345–1357
pubmed: 33555529
doi: 10.1007/s11033-021-06193-4
Dastmalchi N et al (2022) The combined therapy of mir-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer. Med Oncol 39:1–11
doi: 10.1007/s12032-021-01606-7
Oualla K et al (2017) Novel therapeutic strategies in the treatment of triple-negative breast cancer. Therapeutic Adv Med Oncol 9(7):493–511
doi: 10.1177/1758834017711380
Weaver BA (2014) How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677–2681
pubmed: 25213191
pmcid: 4161504
doi: 10.1091/mbc.e14-04-0916
Yu K-D et al (2020) Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 6(9):1390–1396
pubmed: 32789480
doi: 10.1001/jamaoncol.2020.2965
Jeong YJ et al (2016) Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib. Oncol Lett 12(3):2153–2158
pubmed: 27602155
pmcid: 4998568
doi: 10.3892/ol.2016.4852
Walker FE (1993) Paclitaxel (TAXOL®): side effects and patient education issues. In seminars in oncology nursing. Elsevier
Lai D et al (2011) Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 71(7):2728–2738
pubmed: 21349946
doi: 10.1158/0008-5472.CAN-10-2711
Kohlhapp FJ et al (2015) MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene 34(48):5857–5868
pubmed: 25867073
pmcid: 4604012
doi: 10.1038/onc.2015.89
Shi Y et al (2023) Mir-142-3p improves paclitaxel sensitivity in resistant breast cancer by inhibiting autophagy through the GNB2-AKT-mTOR pathway. Cell Signal 103:110566
pubmed: 36539001
doi: 10.1016/j.cellsig.2022.110566
Sun H et al (2019) Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer. Open biology 9(7):180227
pubmed: 31337279
pmcid: 6685930
doi: 10.1098/rsob.180227
Li Y et al (2021) MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer. Pathology-Research and Practice 220:153405
pubmed: 33756128
doi: 10.1016/j.prp.2021.153405
Liang M et al (2022) Overexpression of mir-138-5p sensitizes taxol-resistant epithelial ovarian cancer cells through targeting cyclin-dependent kinase 6. Gynecol Obstet Invest 86(6):533–541
doi: 10.1159/000518510
Huang G et al (2021) Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of mir-138‐5p and activation of AKT/mTOR signaling pathway, vol 9. Pharmacology research & perspectives, p e00720. 1
Axel DI et al (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96(2):636–645
pubmed: 9244237
doi: 10.1161/01.CIR.96.2.636
Wiskirchen J et al (2004) The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol 39(9):565–571
pubmed: 15308939
doi: 10.1097/01.rli.0000133815.22434.55
Fu S et al (2019) Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Lett 448:11–19
pubmed: 30707920
doi: 10.1016/j.canlet.2019.01.026
Kumari S et al (2017) Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother 91:436–445
pubmed: 28475922
doi: 10.1016/j.biopha.2017.04.027
Zhang J et al (2015) MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin, vol 77. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 135–141
Li G et al (2020) Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway. Adv Clin Experimental Med, 29(11)
Cui D et al (2020) Long non-coding RNA TRPM2-AS sponges microRNA-138-5p to activate epidermal growth factor receptor and PI3K/AKT signaling in non-small cell lung cancer. Annals of Translational Medicine, 8(20)
Diehl JA (2002) Cycling to cancer with cyclin D1. Cancer Biol Ther 1(3):226–231
pubmed: 12432268
doi: 10.4161/cbt.72
Matsushime H et al (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71(2):323–334
pubmed: 1423597
doi: 10.1016/0092-8674(92)90360-O
Xiong Y et al (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366(6456):701–704
pubmed: 8259214
doi: 10.1038/366701a0
Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65(10):3980–3985
pubmed: 15899785
doi: 10.1158/0008-5472.CAN-04-3995
Deng C et al (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82(4):675–684
pubmed: 7664346
doi: 10.1016/0092-8674(95)90039-X
Liu X et al (2012) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle 11(13):2495–2506
pubmed: 22739938
doi: 10.4161/cc.20898
Erdmann K et al (2016) MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. J Cancer Res Clin Oncol 142:2249–2261
pubmed: 27562865
doi: 10.1007/s00432-016-2222-4